Researchers Study Nasal Administration of Bionor Pharma's Therapeutic HIV Vaccine [View all]

http://www.sys-con.com/node/2115130

Bionor Pharma's Vacc-4x is an investigational therapeutic HIV vaccine that has already shown in a placebo-controlled Phase IIb study to statistically significant reduce viral load in patients when delivered by injection.
Researchers seek to study if nasal administration with Eurocine Vaccines' Endocine™ will further boost responses to help patients better manage HIV through more accessible and efficient delivery.

Researchers designed Vacc-4x to work by targeting the "Achilles Heel" of the virus, the region of the virus known to be common and stable in all types for HIV. Patients on Vacc-4x have experienced no serious side-effects.
The study, which has now fully enrolled, is conducted by researchers from Oslo University Hospital and funded by The Research Council of Norway (RCN)'s GLOBVAC program.

The study is expected to be completed 1Q 2012.
Bionor Pharma ASA (OSLO: BIONOR), Eurocine Vaccines AB and Oslo University Hospital today announced that the nasal immunization study combining Bionor Pharma's Vacc-4x and Eurocine Vaccines' adjuvant Endocine is fully enrolled.